5 results on '"van Berge Henegouwen M"'
Search Results
2. Paravertebral catheter versus EPidural analgesia in Minimally invasive Esophageal resectioN: a randomized controlled multicenter trial (PEPMEN trial)
- Author
-
Kingma, B. F., Eshuis, W. J., de Groot, E. M., Feenstra, M. L., Ruurda, J. P., Gisbertz, S. S., ten Hoope, W., Marsman, M., Hermanides, J., Hollmann, M. W., Kalkman, C. J., Luyer, M. D. P., Nieuwenhuijzen, G. A. P., Scholten, H. J., Buise, M., van Det, M. J., Kouwenhoven, E. A., van der Meer, F., Frederix, G. W. J., Cheong, E., al Naimi, K., van Berge Henegouwen, M. I., and van Hillegersberg, R.
- Published
- 2020
- Full Text
- View/download PDF
3. Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: a multicenter prospective study (PLASTIC-study)
- Author
-
Brenkman, H. J. F., Gertsen, E. C., Vegt, E., van Hillegersberg, R., van Berge Henegouwen, M. I., Gisbertz, S. S., Luyer, M. D. P., Nieuwenhuijzen, G. A. P., van Lanschot, J. J. B., Lagarde, S. M., de Steur, W. O., Hartgrink, H. H., Stoot, J. H. M. B., Hulsewe, K. W. E., Spillenaar Bilgen, E. J., van Det, M. J., Kouwenhoven, E. A., van der Peet, D. L., Daams, F., van Sandick, J. W., van Grieken, N. C. T., Heisterkamp, J., van Etten, B., Haveman, J. W., Pierie, J. P., Jonker, F., Thijssen, A. Y., Belt, E. J. T., van Duijvendijk, P., Wassenaar, E., van Laarhoven, H. W. M., Wessels, F. J., Haj Mohammad, N., van Stel, H. F., Frederix, G. W. J., Siersema, P. D., Ruurda, J. P., and on behalf of the PLASTIC Study Group
- Published
- 2018
- Full Text
- View/download PDF
4. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): A multicenter observational study
- Author
-
Borggreve, A. S., Mook, S., Verheij, M., Mul, V. E.M., Bergman, J. J., Bartels-Rutten, A., Ter Beek, L. C., Beets-Tan, R. G.H., Bennink, R. J., Van Berge Henegouwen, M. I., Brosens, L. A.A., Defize, I. L., Van Dieren, J. M., Dijkstra, H., Van Hillegersberg, R., Hulshof, M. C., Van Laarhoven, H. W.M., Lam, M. G.E.H., Van Lier, A. L.H.M.W., Muijs, C. T., Nagengast, W. B., Nederveen, A. J., Noordzij, W., Plukker, J. T.M., Van Rossum, P. S.N., Ruurda, J. P., Van Sandick, J. W., Weusten, B. L.A.M., Voncken, F. E.M., Yakar, D., Meijer, G. J., Aleman, B. M.P., Borra, R. J.H., Van Etten, B., Gisbertz, S. S., Goense, L., Haj Mohammad, N., Hartemink, K. J., Kappert, P., Kats-Ugurlu, G., Kodach, L. L., Korteweg, T., Krishnadath, K. K., Langendijk, J. A., De Leng, W. W.J., Meijer, S. L., Potze, J. H., Stoker, J., Vegt, E., Verkooijen, H. M., Vollenbrock, S. E., Wessels, F., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Gastroenterology and Hepatology, AGEM - Re-generation and cancer of the digestive system, Nuclear Medicine, Radiology and Nuclear Medicine, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, CCA - Imaging and biomarkers, Radiotherapy, Oncology, ACS - Diabetes & metabolism, AMS - Restoration & Development, ANS - Brain Imaging, Pathology, and AGEM - Digestive immunity
- Subjects
Cancer Research ,Esophageal Neoplasms ,PREDICTION ,SURGERY ,medicine.medical_treatment ,Esophageal cancer ,FREE DNA ,Study Protocol ,0302 clinical medicine ,Positron Emission Tomography Computed Tomography ,Pathologic complete response ,PATHOLOGICAL COMPLETE RESPONSE ,FDG-PET ,medicine.diagnostic_test ,Image-guided ,Chemoradiotherapy ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Primary tumor ,Neoadjuvant Therapy ,Neoadjuvant chemoradiotherapy ,medicine.anatomical_structure ,Fine-needle aspiration ,Treatment Outcome ,Oncology ,Positron emission tomography ,Esophagectomy ,030220 oncology & carcinogenesis ,GASTROESOPHAGEAL CANCER ,Adenocarcinoma ,030211 gastroenterology & hepatology ,Radiology ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] ,MRI ,medicine.medical_specialty ,DCE-MRI ,PET-CT ,lcsh:RC254-282 ,03 medical and health sciences ,POSITRON-EMISSION-TOMOGRAPHY ,DW-MRI ,Preoperative Care ,medicine ,Genetics ,Humans ,Esophagus ,JUNCTIONAL CANCER ,business.industry ,PERIOPERATIVE CHEMOTHERAPY ,ctDNA ,medicine.disease ,CIRCULATING TUMOR-CELLS ,business ,Follow-Up Studies - Abstract
Contains fulltext : 200332.pdf (Publisher’s version ) (Open Access) BACKGROUND: Nearly one third of patients undergoing neoadjuvant chemoradiotherapy (nCRT) for locally advanced esophageal cancer have a pathologic complete response (pCR) of the primary tumor upon histopathological evaluation of the resection specimen. The primary aim of this study is to develop a model that predicts the probability of pCR to nCRT in esophageal cancer, based on diffusion-weighted magnetic resonance imaging (DW-MRI), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and (18)F-fluorodeoxyglucose positron emission tomography with computed tomography ((18)F-FDG PET-CT). Accurate response prediction could lead to a patient-tailored approach with omission of surgery in the future in case of predicted pCR or additional neoadjuvant treatment in case of non-pCR. METHODS: The PRIDE study is a prospective, single arm, observational multicenter study designed to develop a multimodal prediction model for histopathological response to nCRT for esophageal cancer. A total of 200 patients with locally advanced esophageal cancer - of which at least 130 patients with adenocarcinoma and at least 61 patients with squamous cell carcinoma - scheduled to receive nCRT followed by esophagectomy will be included. The primary modalities to be incorporated in the prediction model are quantitative parameters derived from MRI and (18)F-FDG PET-CT scans, which will be acquired at fixed intervals before, during and after nCRT. Secondary modalities include blood samples for analysis of the presence of circulating tumor DNA (ctDNA) at 3 time-points (before, during and after nCRT), and an endoscopy with (random) bite-on-bite biopsies of the primary tumor site and other suspected lesions in the esophagus as well as an endoscopic ultrasonography (EUS) with fine needle aspiration of suspected lymph nodes after finishing nCRT. The main study endpoint is the performance of the model for pCR prediction. Secondary endpoints include progression-free and overall survival. DISCUSSION: If the multimodal PRIDE concept provides high predictive performance for pCR, the results of this study will play an important role in accurate identification of esophageal cancer patients with a pCR to nCRT. These patients might benefit from a patient-tailored approach with omission of surgery in the future. Vice versa, patients with non-pCR might benefit from additional neoadjuvant treatment, or ineffective therapy could be stopped. TRIAL REGISTRATION: The article reports on a health care intervention on human participants and was prospectively registered on March 22, 2018 under ClinicalTrials.gov Identifier: NCT03474341 .
- Published
- 2018
5. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: Long-term results of a randomized controlled trial
- Author
-
Dinjens Winand NM, Siersema Peter D, ten Kate Fiebo JW, van Berge Henegouwen Mark I, van Heijl Mark, Wijnhoven Bas PL, Kok Tjebbe C, Boonstra Jurjen J, van Lanschot Jan JB, Tilanus Hugo W, and van der Gaast Ate
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background This is a randomized, controlled trial of preoperative chemotherapy in patients undergoing surgery for oesophageal squamous cell carcinoma (OSCC). Patients were allocated to chemotherapy, consisting of 2-4 cycles of cisplatin and etoposide, followed by surgery (CS group) or surgery alone (S group). Initial results reported only in abstract form in 1997, demonstrated an advantage for overall survival in the CS group. The results of this trial have been updated and discussed in the timeframe in which this study was performed. Methods This trial recruited 169 patients with OSCC, 85 patients assigned to preoperative chemotherapy and 84 patients underwent immediate surgery. The primary study endpoint was overall survival (OS), secondary endpoints were disease free survival (DFS) and pattern of failure. Survival has been determined from Kaplan-Meier curves and treatment comparisons made with the log-rank test. Results There were 148 deaths, 71 in the CS and 77 in the S group. Median OS time was 16 months in the CS group compared with 12 months in the S group; 2-year survival rates were 42% and 30%; and 5-year survival rates were 26% and 17%, respectively. Intention to treat analysis showed a significant overall survival benefit for patients in the CS group (P = 0.03, by the log-rank test; hazard ratio [HR] 0.71; 95%CI 0.51-0.98). DFS (from landmark time of 6 months after date of randomisation) was also better in the CS-group than in the S group (P = 0.02, by the log-rank test; HR 0.72; 95%CI 0.52-1.0). No difference in failure pattern was observed between both treatment arms. Conclusions Preoperative chemotherapy with a combination of etoposide and cisplatin significantly improved overall survival in patients with OSCC.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.